Chronic lymphocytic leukemia (CLL) is a malignant disorder of B cell origin, with low incidence in Asian populations. In this study we investigated the HLA-class I A and B allele frequencies in 87 Iranian CLL patients and 64 healthy controls using sequence specific primer-polymerase chain reaction (SSP-PCR) technique. Our results showed increased frequencies of HLA-A11:01 (p=0.02) and HLA-B35:01 (p=0.002) alleles and HLA-A11:01/B35:01 haplotype (p=0.036) and decreased frequencies of HLA-A01:01 (p=0.02), HLA-A26:01 (p=0.03), HLA-B65:01 (p=0.03) and HLA-B53:01 (p<0.00001) alleles in CLL patients compared to the control group.
Introduction
Chronic lymphocytic leukemia (CLL), a hematologic malignancy of CD5 + CD19 + CD23 + B-cells [1] , is considered as the most abundant leukemia in the West [2, 3] . Compared to the Western populations, its frequency is low in Asia and Iran [4] [5] [6] . Clinically, the disease could either be progressive or non-progressive with overall survival time ranging from less than 5 years to more than 30 years. Despite recent identification of several prognostic factors [7, 8] the etiology of CLL remains obscure. Recent investigations on the immunoglobulin heavy chain variable region (IGHV) genes stereotypes of the leukemic B cells suggest involvement of antigen selection in initiation or progression of CLL [9, 10] . Sequencing of the expressed IGHV genes has shown that patients with CLL can be classified into IGHV mutated or unmutated subtypes [11] . Patients having leukemic cells with unmutated IGHV genes usually display a more aggressive disease compared to those with mutated IGHV genes [12, 13] .
HLA genes are the most polymorphic genes which are involved in antigen presentation to T lymphocytes. Expression of certain HLA class I or II alleles has been shown to be associated with a variety of infections and autoimmune or malignant disorders [14] [15] [16] .
Taking into consideration the genetic diversity and variability of HLA alleles in different ethnic populations, different HLA class I and II alleles might be associated to a given disease in different populations.
Association of certain HLA class I [17] or HLA class II [14, 18] alleles with the clinical course of the disease has also been reported in different malignancies.
Apart of a few studies [4, 16, [19] [20] [21] [22] [23] [24] [25] [26] in which the frequency of HLA alleles has been determined in CLL patients from some ethnic populations, association of HLA alleles and CLL prognosis has not been well studied, especially in the Asian CLL patients. In a prior study we reported the frequency of some HLA class I A, B and C antigens in a limited number of CLL patients using the serological microlymphocytotoxicity technique [4] . Later, we reported the HLA class II allele frequencies in a large number of Iranian CLL patients and their correlation to disease progression and IGHV mutation [14] . In the current study, we investigated the frequency of HLA-class I A and B alleles and haplotypes by SSP-PCR technique in the same set of patients. Contrary to our previous serologic HLA class I study, the patients were classified into different molecular and clinical subtypes (progressive and non-progressive, IGHV mutated and unmutated, as well as CD38+ and CD38-subtypes) which allowed analysis of the association of HLA alleles and haplotypes with disease progression.
Materials and Methods

Patients and controls
In the present study, from 87 Iranian CLL patients, 20 ml of heparinized peripheral blood was collected. All patients attended the Hematology and Oncology Clinics of Vail-Asr and Firozgar
Hospitals, affiliated to Tehran University of Medical Sciences. Consent letter was taken from all patients and the study was approved by the Ethical Committee of Tehran University of Medical Sciences. CLL diagnosis and classification of our patients have been described previously [14] .
Patients were considered to have progressive disease if the following criteria were met:
progression during the preceding 3 months in disease-related anemia (hemoglobin <100 g/l), thrombocytopenia (<100 x 109/l) and/or an increase in spleen/liver/lymph node size and/or more than a 2-fold increase in the blood lymphocyte count [14, 27, 28] . HLA typing results were compared with those obtained from 64 Iranian healthy blood donors. Since the age of the subjects does not seem to influence HLA frequency profile, the control group was not age matched with CLL patients and was selected from adult volunteers (23-45 years old; mean age: 34 years).
Typing of HLA-A and HLA-B alleles
HLA class I alleles of patients and controls were defined using low-resolution kits supplied by Qiagen Vertriebs GmbH (Vienna, Austria), based on the manufacturer's instructions.
To define the HLA-A and -B alleles in patients and controls, genomic DNA of each sample was amplified by 24 and 48 cycles of PCR reactions for HLA-A and HLA-B specificities, respectively. Allele frequencies in CLL patients and controls were calculated by direct counting.
Two-locus haplotype (HLA-A/B) frequencies in patients and healthy controls were estimated by maximum-likelihood method according to the expectation-maximization algorithm using Arlequin 2.0 [29] .
Analysis of IGHV genes mutations
Total cellular RNA was isolated from PBMCs of CLL patients using RNA-Bee (BioSite, Taby, Sweden) based on the guanidine thiocyanate phenol chloroform extraction method. First strand cDNA was synthesized from 1-3 ug of total RNA as described previously [14] . To determine the IGHV family gene expression by polymerase chain reaction (PCR), serial dilutions of DNA and cDNA (1:10 to 1:2000) were prepared and PCR amplification was performed using IGHV family-specific degenerative primers. PCR reactions were performed as described [14] . Finally clonal PCR products were purified by excision using the QIAquick gel extraction kit (Qiagen, Hilden, Germany) and were cloned into pGEM-T easy vector (Promega, Southampton, United Kingdom). Sequencing was performed from both directions using the BigDye Terminator Cycle
Sequencing Reaction Kit (Applied Biosystems, Foster City, CA, USA), and T7 and SP6 primers.
For each sample IGHV gene was identified by matching to the closest known human germline gene using the ImMuno-Gene Tics (IMGT) Database (http://imgt.cines.fr) and the IgBLast search (http://www.ncbi.nlm.nih.gov/igblast/). Classification of patients into mutated (n = 56) and unmutated (n = 31) subtypes was based on more than 98% homology in nucleotide sequence of IGHV genes of the leukemic cells [30] .
Statistical analysis
The association of CLL with HLA-I alleles was analyzed by comparing HLA-A and -B alleles frequencies in CLL patients with 64 healthy Iranian controls. Maximum likelihood method was used to evaluate the haplotype frequencies for the two-loci. Chi-Square test for 2×2 tables after
Yates correction was used to define the differences between allele frequencies in patients and controls and patients subgroups, using Epi-Info and SPSS statistical packages (SPSS Inc., Chicago, IL). The odds ratios (OR) with 95% confidence intervals (CI) were calculated and pvalues lower than 0.05 were considered to be significant. The Mann-Whitney U test was also used to compare the time to first treatment (TTFT), progression free survival (PFS) and overall survival (OS) between different CLL subtypes.
Results
HLA-A and B frequencies in CLL patients and controls
In the current study, 87 CLL patients and 64 healthy donors were included. The frequencies of HLA-A and HLA-B alleles in all patients and controls are presented in Tables 1 and 2 was also observed at significantly lower frequency in patients compared to controls (OR=0.17, p=0.03) ( Table 2) .
Frequencies of HLA-I alleles in CLL subtypes
The association of HLA-A and HLA-B alleles to disease progression was analyzed in CLL patients. The frequencies of HLA-A02:01, HLA-A24:01 and HLA-A03:0 alleles were lower in progressive CLL patients, but the differences were not statistically significant. in CLL patients (Table 3) . None of the controls expressed HLA-B35:01 homozygote allele, but the difference between CLL patients and healthy controls was not statistically significant.
HLA-A and -B haplotypes frequency
The frequencies of two loci haplotypes in CLL patients and healthy controls are shown in Table   4 . HLA-A02:01/B35:01, HLA-A24:01/B35:01, HLA-A03:01/B35:01 and HLA-A11:01/B35:01
were the most frequent haplotypes in patients, however, only the frequency of the latter haplotype was significantly higher in the patients compared to the control group (p=0.036). None of the haplotypes was found to be associated to a particular subtype of CLL patients.
Association between TTFT, PFS and OS with HLA I alleles
Comparison of TTFT, PFS and OS in our CLL patients showed no significant correlations between these parameters and frequency of certain HLA-A or -B alleles.
Discussion
Association between HLA antigens and disease initiation or progression has been investigated in a limited number of hematological malignancies, including CLL [14] . The frequency of HLA class I alleles in CLL has been reported in a few ethnic populations (Table 5) . Patients with CLL are classified into IGHV mutated and unmutated subtypes based on the mutational status of the IGHV genes of the leukemic B-cells [11] . These two different subtypes of patients have different molecular and clinical features, in terms of CD38 and ZAP-70 expression and disease progression [31, 32] . CLL patients with mutated IGHV genes tend to express lower levels of CD38 and ZAP-70 molecules with a milder disease, as compared to patients with unmutated
IGHV genes [12, 13, 30 ].
In the current study, we demonstrated the HLA class I A and B alleles frequencies in a group of alleles between their CLL patients and healthy controls [21] , which may partly be due to ethnic differences.
Among the HLA-B alleles we observed a significantly higher frequency of HLA-B35:01 allele in our CLL patients compared to controls (OR=3.51, p=0.002), showing a strong association of this allele with CLL disease. A similar finding was also reported by others [20] , though controversial results have also been published [16, 21, 22, 25, 33 ]. An increased frequency of the HLA-B35 allele has also been reported in some other malignancies and autoimmune diseases from different ethnic populations, including Hodgkin's lymphoma [34] , autoimmune thyroiditis [35] , autoimmune hepatitis [36] autoimmune arthritis [37] , Moyamoya [38] , and pemphigus vulgaris [39] , suggesting a critical correlation of this allele with hematologic malignancies and other pathologic conditions.
In contrast to higher frequency of HLA-B35:01 in CLL patients, a significantly lower frequency of HLA-B65:01 (OR=0.17, p=0.03) and particularly HLA-B53:01 (OR=0.04, p=0.00001) alleles was observed in our patients compared to the healthy controls, suggesting a protective role for these alleles. To our knowledge negative association of these two alleles with CLL has not been reported in other ethnic populations, suggesting ethnical influence of HLA association to CLL disease.
The differences observed in allele frequencies between patients and controls might be interpreted to reflect differences between different subgroups of the Iranian population. Ethnically, the Iranian population is derived from the Caucasian ancestral, though it is composed of different ethnic subpopulations, including Turk, Kurd, Arab, Fars, Balooch, Lor and Turkman people [40] .
These populations are living in different provinces of Iran. However, Tehran, the capital of Iran, is populated with all these subgroups. Thus, since the samples were collected from patients and personnel of two university hospitals located in Tehran, we assume that it is unlikely that the differences observed in allele frequencies between our patients and controls are associated to population subgroups.
Comparison of the frequency of HLA-A alleles in different subtypes of our CLL patients showed a significantly higher frequency of HLA-A32:01 and HLA-A33:01 alleles in IGHV unmutated compared to mutated patients.
A higher frequency of HLA-A33 allele has previously been reported in patients with other disorders [41, 42] . Among the HLA-B alleles, HLA-B52:01 allele was expressed at a higher frequency in CLL patients expressing CD38 molecule, compared to CD38 -patients (OR=4.77, p=0.037). Association between expression of CD38 and/or lack of IGHV mutation with disease progression has been reported in various studies [7, 43, 44] . Accordingly, HLA-A32:01, A33:01 and B52:01 alleles seem to be positively associated to disease progression in our CLL patients.
As we reported previously [14] , non-progressive and IGHV mutated CLL patients had a higher PFS (44 and 37 months, respectively) compared to progressive and unmutated (13 and 9 month, respectively) CLL patients (p=0.006 and 0.001, respectively). Also, IGHV unmutated CLL patients had significantly lower overall survival compared to mutated patients (98% vs. 84%, a The results represent the number (%) of the specified alleles expressed in the study groups, NI= not identified, CI = confidence interval (lower limit-upper limit). Table 4 : HLA-A/B haplotype frequency in CLL patients and controls.
a The results represent the number (%) of the specified alleles expressed in the study groups, NI= not identified, CI = confidence interval (lower limit-upper limit). Data for the most frequent haplotypes are presented in the 
